Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The FKBP12^F36V-iCasp9 fusion protein is a synthetic safety switch engineered into T cells, such as those in the rivogenlecleucel (BPX-501) therapy, to provide a pharmacological method for cell elimination. It consists of a modified human FK506-binding protein (FKBP12) with a phenylalanine-to-valine substitution at position 36, fused to the catalytic domain of human Caspase 9 [1]. This specific mutation creates a unique hydrophobic pocket that allows the protein to bind with high affinity to the synthetic dimerizing agent rimiducid (AP1903), while remaining insensitive to endogenous FKBP12 ligands [2]. Upon administration of rimiducid, the fusion proteins undergo dimerization, which activates the Caspase 9 enzyme and triggers a rapid apoptotic cascade that kills the transduced T cell within hours [3]. This system is primarily used in the context of hematopoietic stem cell transplantation to manage graft-versus-host disease (GvHD), allowing for the selective removal of alloreactive donor T cells while preserving the overall graft-versus-leukemia effect [4]. By providing a 'suicide switch,' this target enhances the safety profile of adoptive cell therapies, enabling more aggressive treatment protocols with a manageable risk of uncontrolled immune reactions [5]. Sources: [1] Di Stasi et al. (2011) NEJM; [2] Zhou et al. (2015) Blood; [3] Gargett & Brown (2014) Front. Pharmacol.; [4] Stavrou et al. (2018) Mol. Ther.; [5] Bellicum Pharmaceuticals Corporate Documentation.
The target functions as a chemical-induced dimerization (CID) system where the small-molecule drug rimiducid acts as a bridge to dimerize the FKBP12-F36V domains. This dimerization brings the attached Caspase 9 molecules into close proximity, triggering their auto-activation and the subsequent initiation of the intrinsic apoptotic pathway, which leads to the rapid death of the host T cell [1][2].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inducible Caspase 9 (iCasp9) fusion protein (iCasp9).